Drug Trial Radar · NCT04103450
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Last checked: Nov 20, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
276
Actual
Start
Sep 19, 2019
Primary completion
Jul 29, 2022
Study completion Jul 29, 2022
Sponsor
- Lead sponsor
- Urovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).
Conditions
- Overactive Bladder
Interventions
VibegronDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%)Time frame: Up to Week 52
- Number of Participants With Clinically Significant Changes in Hematology ParametersTime frame: Up to Week 52
- Number of Participants With Clinically Significant Changes in Chemistry ParametersTime frame: Up to Week 52
- Number of Participants With Clinically Significant Changes in Urinary ParametersTime frame: Up to Week 52
- Number of Participants With Clinically Significant Changes in Coagulation ParameterTime frame: Up to Week 52
- Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)Time frame: Baseline; Week 52
- Change From Baseline in Heart RateTime frame: Baseline; Week 52
Locations
35 sites in 2 countries. Site status is shown where the registry gives one.
Private Practice
Huntsville, Alabama
Clinical Trials Research
Lincoln, California
American Institute of Research
Los Angeles, California
Tri Valley Urology Medical Group
Murrieta, California
Northern California Research Corp
Sacramento, California
San Diego Clinical Trials
San Diego, California
Skyline Urology
Torrance, California
Imagine Research of Palm Beach County - Urology
Boynton Beach, Florida
Tampa Bay Medical Research
Clearwater, Florida
Quantum Clinical Trials
Miami, Florida
Urology Center Of Florida
Pompano Beach, Florida
Precision Clinical Research
Sunrise, Florida
Clinical Research of Central Florida
Winter Haven, Florida
DelRicht Research
New Orleans, Louisiana
Regional Urology, LLC
Shreveport, Louisiana
Boston Clinical Trials Inc - Urology
Boston, Massachusetts
Bay State Clinical Trials, Inc.
Watertown, Massachusetts
Beaumont Hospital Royal Oak - Urology Research
Royal Oak, Michigan
CentraCare Clinic - Adult & Pediatric Urology
Sartell, Minnesota
Poplar Bluff Urology
Poplar Bluff, Missouri
Adult & Pediatric Urology P.C. - Urology
Omaha, Nebraska
Excel Clinical Research - Internal Medicine
Las Vegas, Nevada
Private Practice
Las Vegas, Nevada
Premier Urology Group, LLC
Edison, New Jersey
New Jersey Urology NJU
Englewood, New Jersey
AccuMed Research Associates
Garden City, New York
Urological Surgeons of Long Island
Garden City, New York
Clinical Research Solutions
Middleburg Heights, Ohio
Advances In Health, Inc.
Houston, Texas
Wasatch Clinical Research LLC
Salt Lake City, Utah
Seattle Urology Research Center
Burien, Washington
Centrum Medyczne Linden
Krakow, Poland
Centrum Medyczne PROMED
Krakow, Poland
Medicome Sp. z o.o.
Oświęcim, Poland
Nzoz Heureka
Piaseczno, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.